NIH launched clinical trial of mRNA Nipah virus vaccine
On Jul. 11, 2022, the National Institute of Allergy and Infectious Diseases (NIAID) launched an early-stage clinical trial…
On Jul. 11, 2022, the National Institute of Allergy and Infectious Diseases (NIAID) launched an early-stage clinical trial…
On Jul. 8, 2022, Pfizer and BioNTech announced that the companies had submitted a variation to the European…
On Jul. 7, 2022, Ghana announced the preliminary finding of two cases of Marburg virus disease and if…
On Jul. 7, 2022, Novavax announced that the European Commission had approved a variation to allow SK bioscience…
On Jul. 5, 2022, Novavax announced that the European Commission (EC) had approved the expanded conditional marketing authorization…
On Jul. 5, 2022, the National Institutes of Health and National Cancer Institute announced COVID-19 was the third…
On Jul. 4, 2022, the Democratic Republic of the Congo declared the end of the Ebola outbreak that…
On Jun. 30 2022, Pfizer announced the submission of a New Drug Application (NDA) to the U.S. Food…
On Jun. 30, 2022, BD (Becton, Dickinson) announced that the BD MAX Respiratory Viral Panel (RVP), a new…
On Jun. 23 2022, Novavax announced the filing of a Supplement to a New Drug Submission with Health…
On Jun. 23 2022, Novavax announced that the Nuvaxovid (NVX-CoV2373) COVID-19 vaccine had been recommended for expanded conditional…
On Jun. 23 2022, Novavax announced that the Taiwan Food and Drug Administration had granted emergency use authorization…
On Jun. 23, 2022, Innovation Pharmaceuticals reported that Brilacidin, the Company’s defensin-mimetic drug candidate exhibiting broad-spectrum antiviral activity,…
On Jun. 22, 2022, Merck announced that that the U.S. Food and Drug Administration (FDA) had approved an…
On Jun. 21, 2022, Anixa Biosciences announced the publication of a peer-reviewed journal article in Clinical and Experimental…
On Jun. 17, 2022, Moderna announced that it had received emergency use authorization from the U.S. Food and…
On Jun. 17, 2022, Benaroya Research Institute at Virginia Mason (BRI) announced a 5-year, $11.4 million grant from…
On Jun. 15, 2022, Pfizer and BioNTech announced the European Medicines Agency (EMA) had initiated a rolling review…
On Jun. 14 2022, Oragenics announced the publication of an article co-authored by Oragenics and collaborators at Inspirevax…
On Jun. 14 2022, Pfizer reported data from the Phase 2/3 EPIC-SR (Evaluation of Protease Inhibition for COVID-19…
On Jun. 13 2022, Novavax announced that the Australian Therapeutic Goods Administration (TGA) had granted provisional registration of…
On Jun. 8, 2022, Moderna announced new clinical data on its Omicron-containing bivalent COVID booster candidate, mRNA-1273.214, containing…
On Jun. 7, 2022, Merck and Ridgeback Biotherapeutics announced the Annals of Internal Medicine had published additional data…
On Jun. 7, 2022, Veru announced that is had submitted an emergency use authorization (EUA) application to the…
On Jun. 6, 2022, Pfizer further strengthened its commitment to United States manufacturing with a $120 million investment…
On Jun. 2, 2022, Moderna announced an agreement with the European Commission (EC) to amend their originally agreed…
On Jun. 2, 2022, Novavax announced the submission of a request to the Medicines and Healthcare products Regulatory…
On May 31, 2022, Moderna and Takeda announced the transfer of the marketing authorization for Moderna’s COVID-19 vaccine…
On May 31, 2022, Novavax announced the initiation of its Phase 3 strain change trial to determine if…
On May 30, 2022, The Centre for Health Protection (CHP) of the Department of Health received notification from…